(Q34023727)

30 July 2017

title

Future directions of bone-targeted therapy for metastatic breast cancer (English)

1 reference

30 July 2017

main subject

metastatic breast cancer

1 reference

4

Gabriel N Hortobagyi

1 reference

30 July 2017

5

Naoto T. Ueno

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20808302

4 July 2024

author name string

Tomifumi Onishi

series ordinal

1

1 reference

30 July 2017

Naoki Hayashi

series ordinal

2

1 reference

30 July 2017

Richard L. Theriault

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20808302

4 July 2024

language of work or name

English

0 references

publication date

31 August 2010

1 reference

full work available at URL

30 July 2017

http://www.nature.com/articles/nrclinonc.2010.134.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2010.134

http://www.nature.com/articles/nrclinonc.2010.134

4 July 2024

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2010.134

Nature Reviews Clinical Oncology

4 July 2024

published in

1 reference

30 July 2017

volume

7

1 reference

30 July 2017

issue

11

1 reference

30 July 2017

page(s)

641-651

1 reference

In vitro and in vivo antitumor effects of bisphosphonates

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Transforming growth factor beta1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Metastasis to bone: causes, consequences and therapeutic opportunities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Mechanisms of bone metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Bisphosphonates as anticancer drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Bisphosphonates induce breast cancer cell death in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Bisphosphonates for breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Reduction in new metastases in breast cancer with adjuvant clodronate treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Meta-analysis of clodronate and breast cancer survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Bone resorption predicts for skeletal complications in metastatic bone disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Osteoclast differentiation and activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

The long and the short of bone therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Cellular functions regulated by Src family kinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Src family kinases in tumor progression and metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Targeting protein kinases for bone disease: discovery and development of Src inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Decreased c-Src expression enhances osteoblast differentiation and bone formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Osteoclasts express high levels of pp60c-src in association with intracellular membranes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Cbl associates with Pyk2 and Src to regulate Src kinase activity, alpha(v)beta(3) integrin-mediated signaling, cell adhesion, and osteoclast motility

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Latent bone metastasis in breast cancer tied to Src-dependent survival signals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Evidence that c-src is involved in the process of osteoclastic bone resorption

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Herbimycin A, a pp60c-src tyrosine kinase inhibitor, inhibits osteoclastic bone resorption in vitro and hypercalcemia in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts*1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

The collagenolytic activity of cathepsin K is unique among mammalian proteinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Cathepsin K Knockout Mice Develop Osteopetrosis Due to a Deficit in Matrix Degradation but Not Demineralization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Drug-induced morphea: report of a case induced by balicatib and review of the literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Study of thiol proteases of normal human skin fibroblasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Parathyroid hormone-related protein localization in breast cancers predict improved prognosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Transforming growth factor-beta induces expression of receptor activator of NF-kappa B ligand in vascular endothelial cells derived from bone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Direct osteolysis induced by metastatic murine melanoma cells: role of matrix metalloproteinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Role of TGF-beta in immune-evasion of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

TGF-beta signaling in tumor suppression and cancer progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Mechanisms of TGF-beta signaling from cell membrane to the nucleus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Transforming growth factor-beta1 is the predominant isoform required for breast cancer cell outgrowth in bone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Targeting the transforming growth factor-beta signaling pathway in human cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

TGF-β signalling-related markers in cancer patients with bone metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Involvement of chemokine receptors in breast cancer metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Cancer and the chemokine network

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

A multigenic program mediating breast cancer metastasis to bone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Pilot study of targeted skeletal radiation therapy for bone-only metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Bone imaging in metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Imaging response to systemic therapy for bone metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

A pooled analysis of bone marrow micrometastasis in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Genes associated with breast cancer metastatic to bone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.134

Coexpression of parathyroid hormone related protein and its receptor in early breast cancer predicts poor patient survival.

31 March 2020

1 reference

12 December 2020

Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status

1 reference

12 December 2020

Molecular signature associated with bone marrow micrometastasis in human breast cancer

1 reference

12 December 2020

C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis

1 reference

12 December 2020

The distribution of secondary growths in cancer of the breast. 1889

1 reference

12 December 2020

Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.

1 reference

12 December 2020

Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours

1 reference

12 December 2020

Molecular mechanisms of breast cancer metastases to bone

1 reference

12 December 2020

Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone.

1 reference

12 December 2020

Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density

1 reference

12 December 2020

28

62

6538

P Fournier

2002

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2010.134

4 July 2024

55

63

5028

A Myoui

2003

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2010.134

4 July 2024

130

63

5679

U Woelfle

2003

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2010.134

4 July 2024

Identifiers

1 reference

30 July 2017

1 reference